Ana Segedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Segedi has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Dunja Vesković
Department of Dermatovenerology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
1 shared publication - Milos Nisavic
Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21137 Novi Sad, Serbia
1 shared publication - Olivera Levakov
University of Novi Sad, Faculty of Medicine, Department of Dermatovenereology, Novi Sad, Serbia + University Clinical Center of Vojvodina, Clinic of Dermatovenereology Diseases, Novi Sad, Serbia
1 shared publication
Latest Publications
- 1 January 2026
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 79 (7-8) , 189-196
The role of GLP-1 agonists in the treatment of inflammatory dermatoses uloga GLP-1 agonista u terapiji inflamatornih dermatoza
Introduction. According to the latest studies, glucagon-like peptide-1 receptor agonists, in addition to reducing glycaemia and body weight, also exert strong anti-inflammatory and immunomodulatory effects and are increasingly used to treat chronic inflammatory dermatoses. Glucagon-like peptide-1 receptor agonists and psoriasis vulgaris. In practice, positive effects of glucagon-like peptide-1 receptor agonists on psoriasis severity associated with insulin resistance/diabetes mellitus type 2 and obesity have been observed. In various studies, glucagonlike peptide-1 receptor agonists resulted in significant reductions in psoriasis severity scores and improvements in quality of life. Studies have shown significant improvements in clinical picture and quality of life with glucagon-like peptide-1 receptor agonists in patients with hidradenitis suppurativa associated with obesity. Discussion. Psoriasis and hidradenitis suppurativa are dermatoses characterised by complex immune-mediated inflammatory processes. Clinical studies indicate that the use of glucagon- like peptide-1 receptor agonists leads to improvement of the clinical picture and skin changes in these patients who are obese and have type 2 diabetes/metabolic syndrome. Conclusion. Due to their metabolic, anti-inflammatory, and immunomodulatory effects, glucagon-like peptide-1 receptor agonists represent a promising therapeutic option for inflammatory dermatoses. Their effects are attributable not solely to weight loss but also to direct immunomodulatory action, which explains their efficacy independent of body weight reduction. Further randomised, placebo-controlled clinical trials are required to confirm their effectiveness.
- 1 January 2026
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 79 (7-8) , 189-196
The role of GLP-1 agonists in the treatment of inflammatory dermatoses uloga GLP-1 agonista u terapiji inflamatornih dermatoza
Introduction. According to the latest studies, glucagon-like peptide-1 receptor agonists, in addition to reducing glycaemia and body weight, also exert strong anti-inflammatory and immunomodulatory effects and are increasingly used to treat chronic inflammatory dermatoses. Glucagon-like peptide-1 receptor agonists and psoriasis vulgaris. In practice, positive effects of glucagon-like peptide-1 receptor agonists on psoriasis severity associated with insulin resistance/diabetes mellitus type 2 and obesity have been observed. In various studies, glucagonlike peptide-1 receptor agonists resulted in significant reductions in psoriasis severity scores and improvements in quality of life. Studies have shown significant improvements in clinical picture and quality of life with glucagon-like peptide-1 receptor agonists in patients with hidradenitis suppurativa associated with obesity. Discussion. Psoriasis and hidradenitis suppurativa are dermatoses characterised by complex immune-mediated inflammatory processes. Clinical studies indicate that the use of glucagon- like peptide-1 receptor agonists leads to improvement of the clinical picture and skin changes in these patients who are obese and have type 2 diabetes/metabolic syndrome. Conclusion. Due to their metabolic, anti-inflammatory, and immunomodulatory effects, glucagon-like peptide-1 receptor agonists represent a promising therapeutic option for inflammatory dermatoses. Their effects are attributable not solely to weight loss but also to direct immunomodulatory action, which explains their efficacy independent of body weight reduction. Further randomised, placebo-controlled clinical trials are required to confirm their effectiveness.